In recent trading session, Prime Medicine Inc (NASDAQ:PRME) saw 0.44 million shares changing hands at last check today with its beta currently measuring 1.86. Company’s recent per share price level of $3.17 trading at -$0.12 or -3.46% at last check today assigns it a market valuation of $415.93M. That most recent trading price of PRME’s stock is at a discount of -208.2% from its 52-week high price of $9.77 and is indicating a premium of 29.02% from its 52-week low price of $2.25.
For Prime Medicine Inc (PRME), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.31 in the current quarter.
Prime Medicine Inc (NASDAQ:PRME) trade information
Upright in the red during last session for losing -3.46%, in the last five days PRME remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $3.17 price level, adding 5.65% to its value on the day. Prime Medicine Inc’s shares saw a change of 8.60% in year-to-date performance and have moved 24.36% in past 5-day. Prime Medicine Inc (NASDAQ:PRME) showed a performance of 8.98% in past 30-days.
Wall Street analysts have assigned a consensus price target of 17 to the stock, which implies a rise of 81.35% to its recent value today. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would drop -278.55% in reaching the projected high whereas dropping to the targeted low would mean a loss of -278.55% for stock’s current value.
Prime Medicine Inc (PRME) estimates and forecasts
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 5.81M for the same. And 5 analysts are in estimates of company making revenue of 4.55M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -193.88% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 26.60% while estimates for its earnings growth in next 5 years are of 20.17%.
On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 2.41 shares of worth $7.61 million or 1.84% of the total outstanding shares. The later fund manager was in possession of 2.23 shares on Dec 31, 2024, making its stake of worth around $7.03 million in the company or a holder of 1.70% of company’s stock.
